should i use glp 1 for weight loss Chart: in 8 Americans Now GLP-1 Drugs GLP-1 receptor agonists | How

Eli Lilly announced that Retatrutidethe first-in-class GIP, GLP-1, and glucagon triple agonistachieved an average weight loss of 28.7% at 68 weeks in the TRIUMPH-4 Phase 3 trial

In the Phase 3 REDEFINE-1 trial, adding cagrilintide to semaglutide pushed average weight loss from 14.9% to 20.4%

Because tirzepatide influences multiple metabolic pathways, some individuals notice more steady progress compared to previous treatments

As the dosage increases over time, the appetite-suppressing effects often become stronger and more consistent, helping patients develop healthier eating habits and steady progress toward their weight-loss goals